Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis

Safety of S1P Modulators in Patients with Immune-Mediated Diseases: A Systematic Review and Meta-Analysis

(2021) Juan S. Lasa et al.   DRUG SAFETY

Breaking the therapeutic ceiling in drug development in ulcerative colitis

(2021) Dahham Alsoud et al.   Lancet Gastroenterology & Hepatology

Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial

(2021) Brian G Feagan et al.   LANCET

Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis

(2021) William J. Sandborn et al.   NEW ENGLAND JOURNAL OF MEDICINE

First- and Second-line Pharmacotherapies for Patients with Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis

(2020) Siddharth Singh et al.   Clinical Gastroenterology and Hepatology

Safety of Janus Kinase Inhibitors in Patients with Inflammatory Bowel Diseases or Other Immune-mediated Diseases: a Systematic Review and Meta-Analysis

(2020) Pablo Olivera et al.   GASTROENTEROLOGY

948 A NOVEL SUBCUTANEOUS INFLIXIMAB (CT-P13) IN PATIENTS WITH ACTIVE CROHN'S DISEASE AND ULCERATIVE COLITIS: WEEK54 AND SWITCHING RESULTS FROM A MULTICENTER, RANDOMISED CONTROLLED PIVOTAL TRIAL

(2020) Walter Reinisch et al.   GASTROENTEROLOGY

CINeMA: An approach for assessing confidence in the results of a network meta-analysis

(2020) Adriani Nikolakopoulou et al.   PLOS MEDICINE

JAK selectivity for inflammatory bowel disease treatment: does it clinically matter?

(2019) Silvio Danese et al.   GUT

Efficacy and Safety of Vedolizumab Subcutaneous Formulation in a Randomized Trial of Patients With Ulcerative Colitis

(2019) William J. Sandborn et al.   GASTROENTEROLOGY

Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis

(2019) Bruce E. Sands et al.   NEW ENGLAND JOURNAL OF MEDICINE

Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis

(2019) Bruce E. Sands et al.   NEW ENGLAND JOURNAL OF MEDICINE

Systematic review with network meta-analysis: the impact of medical interventions for moderate-to-severe ulcerative colitis on health-related quality of life

(2018) Paschalis Paschos et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

JAK inhibition in inflammatory bowel disease

(2017) Pablo Olivera et al.   Expert Review of Clinical Immunology

Efficacy and safety of golimumab 52-week maintenance therapy in Japanese patients with moderate to severely active ulcerative colitis: a phase 3, double-blind, randomized, placebo-controlled study-(PURSUIT-J study)

(2017) Toshifumi Hibi et al.   JOURNAL OF GASTROENTEROLOGY

Ulcerative colitis

(2017) Ryan Ungaro et al.   LANCET

Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis

(2017) William J. Sandborn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Next generation of small molecules in inflammatory bowel disease

(2016) Pablo Olivera et al.   GUT

Ranking treatments in frequentist network meta-analysis works without resampling methods

(2015) Gerta Rücker et al.   BMC Medical Research Methodology

Low-dose Infliximab for Induction and Maintenance Treatment in Chinese Patients With Moderate to Severe Active Ulcerative Colitis

(2015) Xue-Liang Jiang et al.   JOURNAL OF CLINICAL GASTROENTEROLOGY

First trough level of infliximab at week 2 predicts future outcomes of induction therapy in ulcerative colitis—results from a multicenter prospective randomized controlled trial and its post hoc analysis

(2015) Taku Kobayashi et al.   JOURNAL OF GASTROENTEROLOGY

Biological Agents for Moderately to Severely Active Ulcerative Colitis

(2014) Silvio Danese et al.   ANNALS OF INTERNAL MEDICINE

Adalimumab versus infliximab for the treatment of moderate to severe ulcerative colitis in adult patients naïve to anti-TNF therapy: An indirect treatment comparison meta-analysis

(2014) Kristian Thorlund et al.   Journal of Crohns & Colitis

Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement

(2013) David Moher   ANNALS OF INTERNAL MEDICINE

Subcutaneous Golimumab Induces Clinical Response and Remission in Patients With Moderate-to-Severe Ulcerative Colitis

(2013) William J. Sandborn et al.   GASTROENTEROLOGY

Subcutaneous Golimumab Maintains Clinical Response in Patients With Moderate-to-Severe Ulcerative Colitis

(2013) William J. Sandborn et al.   GASTROENTEROLOGY

Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis

(2013) Yasuo Suzuki et al.   JOURNAL OF GASTROENTEROLOGY

Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis

(2013) Brian G. Feagan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative Colitis

(2011) William J. Sandborn et al.   GASTROENTEROLOGY

Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial

(2011) W. Reinisch et al.   GUT

Interpreting Indirect Treatment Comparisons and Network Meta-Analysis for Health-Care Decision Making: Report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: Part 1

(2011) Jeroen P. Jansen et al.   VALUE IN HEALTH

Systematic review: the costs of ulcerative colitis in Western countries

(2010) R. D. COHEN et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS